JO3229B1 - العمل على استقرار الهرمون المنبه للجريب - Google Patents

العمل على استقرار الهرمون المنبه للجريب

Info

Publication number
JO3229B1
JO3229B1 JOP/2011/0231A JOP20110231A JO3229B1 JO 3229 B1 JO3229 B1 JO 3229B1 JO P20110231 A JOP20110231 A JO P20110231A JO 3229 B1 JO3229 B1 JO 3229B1
Authority
JO
Jordan
Prior art keywords
stabilization
salts
fsh
pharmaceutically acceptable
addition
Prior art date
Application number
JOP/2011/0231A
Other languages
English (en)
Inventor
Louise Bagger Heidi
SJOGREN Helen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3229B1 publication Critical patent/JO3229B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بصفة عامة بمجال تثبيت صيغ الهرمونات المنشطة للحويصلات (FSH)، وبصفة خاصة صيغ FSH السائلة. يتحقق التثبيت بواسطة إضافة أملاح تشتمل على كاتيونات معدنية قلوية مقبولة صيدلانياً، وفي النماذج المفضلة يتحقق التثبيت بإضافة أملاح تشتمل على كاتيونات معدنية قلوية مقبولة صيدلانياً، وفي النماذج المفضلة يتم ذلك من خلال إضافة أملاح مقبولة صيدلانياً، مثل أملاح الصوديوم أو أملاح البوتاسيوم.
JOP/2011/0231A 2010-07-30 2011-07-21 العمل على استقرار الهرمون المنبه للجريب JO3229B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins

Publications (1)

Publication Number Publication Date
JO3229B1 true JO3229B1 (ar) 2018-03-08

Family

ID=43216624

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0231A JO3229B1 (ar) 2010-07-30 2011-07-21 العمل على استقرار الهرمون المنبه للجريب

Country Status (27)

Country Link
US (3) US8993732B2 (ar)
EP (3) EP2417982A1 (ar)
JP (3) JP5860047B2 (ar)
KR (2) KR101991756B1 (ar)
CN (2) CN105106939A (ar)
AR (1) AR082776A1 (ar)
AU (1) AU2011284702C1 (ar)
BR (1) BR112013002312B1 (ar)
CA (1) CA2805864A1 (ar)
DK (1) DK2598160T3 (ar)
ES (1) ES2623634T3 (ar)
HR (1) HRP20170386T1 (ar)
HU (1) HUE033592T2 (ar)
IL (2) IL223821A (ar)
JO (1) JO3229B1 (ar)
LT (1) LT2598160T (ar)
MX (2) MX356951B (ar)
NZ (2) NZ606366A (ar)
PL (1) PL2598160T3 (ar)
PT (1) PT2598160T (ar)
RS (1) RS55772B1 (ar)
RU (1) RU2574012C2 (ar)
SA (1) SA114350786B1 (ar)
SI (1) SI2598160T1 (ar)
TW (1) TWI439283B (ar)
WO (1) WO2012013742A2 (ar)
ZA (1) ZA201209497B (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AP2016009159A0 (en) * 2013-11-12 2016-04-30 Cadila Healthcare Ltd Formulation for gonadotropins
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
TW201938190A (zh) 2017-12-07 2019-10-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的ph 7之可注射溶液
TWI813604B (zh) 2017-12-07 2023-09-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT814841E (pt) 1995-03-21 2002-03-28 Applied Research Systems Formulacoes liquidas de hcg
DE69733889T3 (de) * 1996-05-29 2009-10-22 Delsitech Oy Lösliche oxide für biologische anwendungen
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
BRPI0508798A (pt) * 2004-04-07 2007-09-04 Ares Trading Sa formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
NZ586588A (en) * 2008-02-08 2012-10-26 Biogenerix Ag Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Also Published As

Publication number Publication date
US9463221B2 (en) 2016-10-11
RU2012157154A (ru) 2014-09-10
EP2598160B1 (en) 2017-02-22
US20130210727A1 (en) 2013-08-15
SA114350786B1 (ar) 2015-07-09
KR20130143692A (ko) 2013-12-31
JP2013532677A (ja) 2013-08-19
ES2623634T3 (es) 2017-07-11
NZ628962A (en) 2016-01-29
CA2805864A1 (en) 2012-02-02
IL249920A0 (en) 2017-03-30
AU2011284702A1 (en) 2013-02-07
BR112013002312B1 (pt) 2021-09-21
KR101991756B1 (ko) 2019-06-21
EP2598160A2 (en) 2013-06-05
US20150265681A1 (en) 2015-09-24
BR112013002312A2 (pt) 2018-03-20
PT2598160T (pt) 2017-03-30
CN103052398A (zh) 2013-04-17
DK2598160T3 (en) 2017-03-27
EP2417982A1 (en) 2012-02-15
JP2016102127A (ja) 2016-06-02
WO2012013742A2 (en) 2012-02-02
WO2012013742A3 (en) 2012-04-19
HRP20170386T1 (hr) 2017-05-05
NZ606366A (en) 2014-08-29
LT2598160T (lt) 2017-04-10
SI2598160T1 (sl) 2017-07-31
AU2011284702B2 (en) 2015-05-14
EP3144010A1 (en) 2017-03-22
HUE033592T2 (hu) 2017-12-28
IL223821A (en) 2017-01-31
PL2598160T3 (pl) 2017-06-30
AR082776A1 (es) 2013-01-09
AU2011284702C1 (en) 2015-09-03
US20170216405A1 (en) 2017-08-03
TWI439283B (zh) 2014-06-01
CN103052398B (zh) 2015-09-16
MX341464B (es) 2016-08-22
TW201208694A (en) 2012-03-01
MX356951B (es) 2018-06-21
ZA201209497B (en) 2013-08-28
JP2018048188A (ja) 2018-03-29
JP5860047B2 (ja) 2016-02-16
MX2013000681A (es) 2013-02-27
JP6522711B2 (ja) 2019-05-29
US8993732B2 (en) 2015-03-31
KR20180008916A (ko) 2018-01-24
RS55772B1 (sr) 2017-07-31
RU2574012C2 (ru) 2016-01-27
CN105106939A (zh) 2015-12-02
KR101820115B1 (ko) 2018-01-18

Similar Documents

Publication Publication Date Title
JO3229B1 (ar) العمل على استقرار الهرمون المنبه للجريب
MY170302A (en) Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its use
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
JO3241B1 (ar) عملية لتحضير محلول مائي يتألف على الاقل من كربونات هيدروجين الكيل خبأ واستخدامه
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
MY183312A (en) Pharmaceutical formulation
GEAP202213376A (en) Inhibitors of influenza viruses replication
MX348823B (es) Formulaciones estables de linaclotida.
PH12013500976A1 (en) Antiviral compounds
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2014CN04530A (ar)
GB201113754D0 (en) Composition
MX352563B (es) Composiciones para el cuidado oral que contienen carbonato de calcio y silice.
MX368933B (es) Dispersiones oleosas de agroquimicos estables.
IN2014MN00859A (ar)
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX337612B (es) Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.
TR201009168A2 (tr) Suda dağılan sefpodoksim proksetil formülasyonları.
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
IN2013MU02442A (ar)
WO2013064326A3 (de) Arjunolsäure zur erhöhung der sebumproduktion
WO2011124861A3 (fr) Utilisation de composés oligosaccharides dérivés du xanthane comme agent énergisant